Home>>Signaling Pathways>> Metabolism>> Metabolic Syndrome>>sPLA2 Inhibitor

sPLA2 Inhibitor (Synonyms: KH064, Secretory Phospholipase A2 Inhibitor)

Catalog No.GC44943

sPLA2 Inhibitor, a D-tyrosine derivative, is an orally active, potent secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 29 nM for human nonpancreatic secretory PLA2 isoform IIa (hnpsPLA2-IIa).

Products are for research use only. Not for human use. We do not sell to patients.

sPLA2 Inhibitor Chemical Structure

Cas No.: 393569-31-8

Size Price Stock Qty
500μg
$60.00
In stock
1mg
$103.00
In stock
5mg
$419.00
In stock
10mg
$756.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Secreted phospholipases A2 (sPLA2s) are a diverse family of low molecular weight PLA2s with tissue-specific expression patterns and actions. The group IIA sPLA2 (sPLA2-IIA) was originally purified from platelets and exudates from patients with rheumatoid arthritis. Its expression can be induced by inflammatory mediators, and mouse studies suggest that it may play roles in colorectal polyposis, atherosclerosis, and bacterial infections. sPLA2 inhibitor is an orally active inhibitor of sPLA2-IIA. It protects against intestinal reperfusion injury in rats when given at 10 mg/kg orally. sPLA2 inhibitor also attenuates NF-κB signaling in lung cancer cells and protects against diet-induced metabolic syndrome in rats.

Reviews

Review for sPLA2 Inhibitor

Average Rating: 5 ★★★★★ (Based on Reviews and 7 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for sPLA2 Inhibitor

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.